Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
Zealand hopes that the appeal of fewer side effects will be a major draw for its treatment. According to Bloomberg, Zealand ...
Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...
SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback